循环肿瘤 DNA：预测结直肠癌复发及指导治疗的新工具。
Circulating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer.
作者信息
Vo-Quang Erwan, Gandini Annalice, Taly Valerie, Laurent-Puig Pierre, Zaanan Aziz, Taieb Julien
机构信息
Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, AP-HP, Paris, France.
Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, AP-HP, Paris, France; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université Paris Cité, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France, UMR-S1138, CNRS SNC5096, Équipe labélisée Ligue Nationale contre le cancer, Centre de Recherche des Cordeliers, Paris, France.
出版信息
Clin Res Hepatol Gastroenterol. 2025 May 7;49(7):102611. doi: 10.1016/j.clinre.2025.102611.
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with diverse applications across different stages of colorectal cancer management. One of its primary roles is as a prognostic biomarker for detecting post-surgical molecular residual disease and predicting recurrence risk. Compared to traditional biomarkers and tissue biopsies, ctDNA provides a minimally invasive, dynamic, and comprehensive representation of tumor burden and molecular heterogeneity. However, challenges persist in standardizing ctDNA testing, improving sensitivity for early-stage disease, and ensuring widespread accessibility. In this review, we explore the biological characteristics of ctDNA, the methodologies for its detection, and its broad clinical applications in both localized and metastatic colorectal cancer.
循环肿瘤DNA（ctDNA）已成为一种有前景的生物标志物，在结直肠癌管理的不同阶段有多种应用。其主要作用之一是作为一种预后生物标志物，用于检测术后分子残留疾病并预测复发风险。与传统生物标志物和组织活检相比，ctDNA提供了肿瘤负荷和分子异质性的微创、动态且全面的表征。然而，在标准化ctDNA检测、提高对早期疾病的敏感性以及确保广泛可及性方面仍存在挑战。在本综述中，我们探讨了ctDNA的生物学特性、其检测方法及其在局限性和转移性结直肠癌中的广泛临床应用。
Zotero 插件